Similar findings were independently confirmed in a cohort of large size (n = 399), in which the patients of urothelial tumors [21] and melanoma [23] receiving anti-PD1/PD-L1 therapy were combined, where the high-senescore group displayed a significantly longer OS (Fig. 6J), and a higher proportion of overall response (31% versus 19%) (Fig. 6K). The gene discussed is CD274; the disease is melanoma.